Encapset Technologies: Solving High-Payload Formulation

Bioavailability gets most of the attention in delivery-system marketing, but a formulator can lose a product long before absorption is tested. The failure may be much simpler: too much carrier, too little active and a serving size consumers will not accept.

That is the problem behind Encapset Technologies. Samarth Biorigins describes Encapset as a lipid-and-surfactant encapsulation platform designed for high nutrient loading, with the company stating that active loading can extend above 85% for the technology.

That number is commercially interesting, but it should be treated as a platform specification that still needs product-specific verification. High loading is valuable only if the ingredient remains stable, processable and capable of delivering the intended release or dispersion profile.

Payload is the quiet constraint behind capsule count

Imagine a formulation that needs 500 mg of an active per daily serving. If the delivery system contains only 25% active by weight, the formulation needs 2,000 mg of delivery-system powder before other excipients are added. That can push the product into multiple capsules or a large scoop.

If another system can carry a much higher proportion of active while retaining the required performance, the finished serving can become smaller.

This is why payload matters commercially. It affects capsule count, tablet weight, sachet size, freight, packaging and consumer compliance with the serving instructions.

Our first position is that active loading should be discussed in every enhanced-delivery proposal, not only when the number looks impressive.

Encapsulation efficiency is not the same as active loading

These two terms are often confused. Encapsulation efficiency describes how much of the active introduced during manufacturing becomes associated with the delivery system. Active loading describes how much active is present relative to the final mass of the carrier system.

A formulation can capture nearly all of a small amount of active and still have low loading because the carrier mass is large. Conversely, a high-loading system still needs acceptable encapsulation or association behaviour if that is central to the delivery mechanism.

For B2B buyers, both numbers can matter. Loading influences finished-product economics and serving size. Encapsulation efficiency helps describe the manufacturing and structural performance of the system.

A supplier should be able to state which number is being quoted and how it was measured.

Why high payload can create a stability trade-off

Carriers occupy physical space and can help stabilise an active. Removing too much carrier in pursuit of higher loading can reduce the structural margin of the system.

Depending on the technology, high active concentration may increase aggregation, crystallisation, leakage, poor dispersion or variability during manufacturing. The exact risk depends on the active and carrier chemistry.

That means the goal is not maximum loading at any cost. The goal is the highest practical loading that still meets the critical quality attributes for the intended product.

Our second position is that an 85% loading claim is less useful than a validated loading range linked to stability and performance. Product teams need the operating window, not the record attempt.

The formulation economics can change sharply at high dose

Carrier burden is easy to ignore when comparing raw-material prices. A low-loading ingredient may look cheaper per kilogram but require much more total powder to deliver the same amount of active.

The correct comparison is cost per finished serving. Include active concentration, carrier mass, capsule shells or sachet size, manufacturing yield and packaging.

For tablets, high carrier load can also affect compression and tablet dimensions. For gummies, every gram of carrier competes with sweeteners, gelling agents and flavours for limited formulation space. For drink powders, carrier solids can change mouthfeel and scoop size.

A delivery technology becomes commercially valuable when it reduces one of these constraints without creating a larger problem elsewhere.

What Encapset Technologies says it is designed to solve

Samarth Biorigins states that Encapset uses natural lipids and surfactants and is designed to provide high active loading alongside particle-size reduction, dispersion and controlled delivery. The company presents an active-loading figure above 85% at the platform level.

Those statements give buyers a clear list of items to verify on the specific Encapset ingredient under consideration. Ask for active assay, carrier composition, loading calculation, particle data, dispersion behaviour, release profile and stability.

If the commercial ingredient is Encapset Curcumin, the evidence should belong to that formulation. If it is Encapset CoQ10 or another active, do not assume identical loading or release behaviour merely because the platform name is the same.

The platform creates a design philosophy. The product specification proves how that philosophy worked for a particular active.

High loading matters most when the dose is large

For a potent ingredient used at 5 or 10 mg per day, a carrier-heavy delivery system may still fit easily into one capsule. The payload advantage may have little commercial impact.

For nutrients used at hundreds of milligrams, the calculation changes. Carrier mass can dominate the serving and make an otherwise attractive technology impractical.

This is why payload discussions should always include the intended dose. A percentage without a dose is detached from product design.

The same principle applies to combination products. A formula containing several enhanced-delivery ingredients can accumulate carrier mass quickly. Each ingredient may be technically elegant on its own while the blend becomes too bulky.

A practical calculation before formulation begins

Before ordering samples, calculate the delivery-system mass required per serving.

Take the target active dose and divide it by the active fraction of the ingredient. A 300 mg active dose supplied in a powder that is 30% active requires 1,000 mg of that ingredient. At 75% active, the same target requires 400 mg.

That difference may decide whether the product fits one capsule, two capsules or a sachet. It can also change cost and excipient space.

This calculation is simple enough to perform in a spreadsheet, yet it is frequently postponed until after the ingredient has been selected.

Our third position is that payload maths belongs at concept stage, before sensory trials, branding or packaging design.

Release profile and dispersion still have to be proven

A high-payload system is not useful if the active fails to disperse or release appropriately. Ask how release is measured and whether the method reflects the intended route and dosage form.

For an oral ingredient, simulated gastrointestinal testing can provide mechanistic information, but a human bioavailability claim still requires appropriate human evidence. For a beverage, physical dispersion and stability may be more important during early development.

This is where product teams need to resist a common shortcut: treating particle-size reduction, high loading and better bioavailability as one combined claim. They are different attributes and should be supported by different measurements.

A strong dossier connects them without pretending one proves the others.

Scale-up can change the loading-performance balance

Laboratory encapsulation may use mixing, shear or solvent conditions that are difficult to reproduce at commercial scale. Small changes can alter particle size, distribution or the amount of active associated with the carrier.

That makes batch-to-batch data important. A single R&D batch at a high loading level is not enough to establish commercial consistency.

Ask whether the supplier has pilot and production-scale data at the proposed loading. Review trends in assay, particle attributes and release or dispersion rather than looking only at pass/fail certificates.

Samarth's Custom Solutions material describes pilot production, scale-up and validation testing. Those capabilities are relevant to Encapset, but the proof still needs to be ingredient-specific.

When a lower loading system may still be the better choice

High loading is not automatically the best decision. A lower loading platform may offer better stability, taste masking, release control or human evidence for the specific application.

If the final serving is small anyway, the payload advantage may not justify switching from a well-established system. Product teams should compare the whole value proposition.

There is an honest uncertainty here: the optimal active-to-carrier ratio is specific to the active, desired release profile and manufacturing process. A universal maximum would ignore those differences.

The decision should therefore be framed as a trade-off: how much active can the system carry while still meeting every specification that matters to the finished product?

The more useful way to talk about Encapset

Encapset Technologies can be positioned around a real formulation problem: carrier burden. That is more tangible to product developers than a generic statement about advanced encapsulation.

For each Encapset ingredient, show the active loading, define how it was measured, provide the critical quality attributes and demonstrate that the system remains stable and usable at that loading.

If the technology reduces capsule count or enables a high-dose formula that would otherwise be impractical, that is a concrete B2B benefit. If it does not change the finished product materially, the loading percentage is only a technical curiosity.

The best high-payload system is therefore not the one with the biggest number. It is the one that creates a smaller, stable and manufacturable product without sacrificing the evidence required for the intended claim.

The payload claim should be tied to the finished serving

A simple formulation worksheet can turn a high-loading percentage into a commercial decision. Enter the active dose, verified loading, total delivery-system mass and the available space in the capsule, tablet or sachet. Then add the other actives and excipients.

This calculation is where Encapset Technologies becomes meaningful. If higher loading materially reduces carrier burden while the ingredient still meets stability, dispersion and release specifications, the platform has solved a real product constraint. If the serving size barely changes, payload should not dominate the buying decision.